Vimarsana
Biggest News Aggregation in the World

Page 18 - Published August News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Published August. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Published August Today - Breaking & Trending Today

The Impact of a Clinical Pharmacist on Immunosuppressive Medication Adherence in Kidney Transplant Patients - Vimarsana News

The Impact of a Clinical Pharmacist on Immunosuppressive Medication Adherence in Kidney Transplant Patients

Studies show that patients who had pharmacists as part of their transplant-related care had a significant improvement in clinical outcomes.

How Netflix And YouTube Changed Entertainment Forever | CNBC Marathon - Vimarsana News

How Netflix And YouTube Changed Entertainment Forever | CNBC Marathon

From Netflix and YouTube to AMC, CNBC Marathon explores the future of entertainment. Over the past 25 years, Netflix revolutionized the film and television industry. The company amassed over 220 million subscribers across 190 countries, billions of hours watched for show Stranger Things and racked in 226 award wins. However, in 2022, things began looking rather different for the storied streamer while fighting an uphill battle to remain relevant in the streaming wars. In Q2 of 2022, Netflix lost nearly 1 million subscribers as rival Disney+ added roughly 14 million new subscribers. Movie theat...

Analysis Details Effects of Dapagliflozin on Total Events in HFmrEF, HFpEF - Vimarsana News

Analysis Details Effects of Dapagliflozin on Total Events in HFmrEF, HFpEF

A prespecified analysis of the DELIVER trial provides insight into the effects of dapagliflozin use on total heart failure events in patients with mildly reduced or preserved ejection fraction.

10 Years of SGLT2 Inhibitors: A Decade of Redefining Cardiometabolic Care - Vimarsana News

10 Years of SGLT2 Inhibitors: A Decade of Redefining Cardiometabolic Care

This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.

A Hidden Crisis: The Need for Treatments in Notalgia Paresthetica - Vimarsana News

A Hidden Crisis: The Need for Treatments in Notalgia Paresthetica

A silent disease characterized as a chronic cutaneous neuropathy, notalgia paresthetica has an unmet need yet to be fully understood and, dermatologists argue, an FDA-approved treatment could help improve understanding of the etiology and prevalence of this disease.